Skip to content
Screener

Vir Biotechnology, Inc. VIR Business Segments — Contract manufacturing

Similar metrics at other companies

Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Contract manufacturing
$4.9M-64.8%
Cadence Design Systems logo
CDNSReportable Segment — Manufacturing costs
$104.48M+3.0%
Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Research And Development Expense, Contract Manufacturing
$2.04M-76.1%
Vaxcyte, Inc. logo
PCVXReportable Segment — Acquired manufacturing rights
$0
IPG Photonics logo
IPGPReportable Segment — Other manufacturing expenses
$36.84M+19.3%
Ouster logo
OUSTReportable Segment — Product manufacturing costs
$22.5M+43.0%

Other financials

Income statement

See full
Revenue$238.9M+19,583%
Gross profit$238.9M+19,763%
Operating income$73.5M+162%
Net income$80.1M+172%
EPS (diluted)$0.47+159%

Balance sheet

See full
Cash & equivalents$287.6M-6.1%
Total debt$93.3M-8.8%
Total equity$982.5M+3.7%
Total assets$1.2B+1.9%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$32.0K-98.7%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.48B+111%
Enterprise value$1.29B+159%
P/S4.9×-32.1×

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-92.4%-45.5pp
Net margin-83%-40.9pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-26.1%-7.9pp
Debt / equity0.1×0.0×
Current ratio-1.0×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept vir:ResearchAndDevelopmentContractManufacturing.

The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053549
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Less: Segment expenses (1)
Cost of revenue1111
Research and development
Contract manufacturing23,96714,06359,97423,399
Personnel (2)28,51233,16560,04066,883
Clinical costs22,53220,36148,66640,967
Licenses, collaborations and contingent consideration, net41,21111,30138,40247,892
Other R&D (3)19,06118,61937,12337,013

Item 1. Financial Statements (unaudited)

FAQ

What is Vir Biotechnology, Inc.'s business segments — contract manufacturing?
Vir Biotechnology, Inc. (VIR) reported business segments — contract manufacturing of $23.97M in Q2 2026.
How has Vir Biotechnology, Inc.'s business segments — contract manufacturing changed year-over-year?
Vir Biotechnology, Inc.'s business segments — contract manufacturing increased by 70.4% year-over-year, from $14.06M to $23.97M.
What is the long-term trend for Vir Biotechnology, Inc.'s business segments — contract manufacturing?
Over 3 years (2022 to 2025), Vir Biotechnology, Inc.'s business segments — contract manufacturing has grown at a -0.2% compound annual growth rate (CAGR), from $47.96M to $47.62M.
What does business segments — contract manufacturing mean?
Refers to the expenses incurred by the segment for outsourcing the production of clinical or commercial drug supplies to third-party manufacturers. Monitoring this cost helps assess the company's reliance on external manufacturing partners and the scalability of its production processes.

Ask your AI about Vir Biotechnology, Inc.'s business segments — contract manufacturing.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude